About Podocalyxin
Podocalyxin (PODXL) is a protein
from Homo sapiens identified by UniProt accession
O00592, 558 residues long.
MolForge cross-references it against 0 known binders and
312 disease associations.
Target properties
| Protein name | Podocalyxin |
| UniProt accession | O00592 |
| Gene | PODXL |
| Organism | Homo sapiens |
| Length | 558 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (312)
Diseases linked to this target (Open Targets).
- familial nephrotic syndrome · score 0.46
- systolic blood pressure · score 0.45
- diastolic blood pressure · score 0.40
- pulse pressure measurement · score 0.38
- young-onset Parkinson disease · score 0.37
- atypical juvenile parkinsonism · score 0.37
- urate measurement · score 0.31
- bone density · score 0.31
- hemoglobin measurement · score 0.31
- blood pressure · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00592-F1 | alphafold | PREDICTED | 52.91 | — |
Amino-acid sequence (558 residues)
MRCALALSAL LLLLSTPPLL PSSPSPSPSP SQNATQTTTD SSNKTAPTPA SSVTIMATDT AQQSTVPTSK ANEILASVKA TTLGVSSDSP GTTTLAQQVS GPVNTTVARG GGSGNPTTTI ESPKSTKSAD TTTVATSTAT AKPNTTSSQN GAEDTTNSGG KSSHSVTTDL TSTKAEHLTT PHPTSPLSPR QPTSTHPVAT PTSSGHDHLM KISSSSSTVA IPGYTFTSPG MTTTLLETVF HHVSQAGLEL LTSGDLPTLA SQSAGITASS VISQRTQQTS SQMPASSTAP SSQETVQPTS PATALRTPTL PETMSSSPTA ASTTHRYPKT PSPTVAHESN WAKCEDLETQ TQSEKQLVLN LTGNTLCAGG ASDEKLISLI CRAVKATFNP AQDKCGIRLA SVPGSQTVVV KEITIHTKLP AKDVYERLKD KWDELKEAGV SDMKLGDQGP PEEAEDRFSM PLIITIVCMA SFLLLVAALY GCCHQRLSQR KDQQRLTEEL QTVENGYHDN PTLEVMETSS EMQEKKVVSL NGELGDSWIV PLDNLTKDDL DEEEDTHL
Explore Podocalyxin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets